Cases & Deals

  • Home
  • Practices
  • Verastem develops global patent portfolio for COPIKTRA® (duvelisib)

Share

Verastem develops global patent portfolio for COPIKTRA® (duvelisib)

December 2016

Client(s) Verastem, Inc.

Jones Day represents Verastem, Inc. in the establishment of a global patent portfolio related to COPIKTRA® (duvelisib), a small molecule approved for the treatment of relapsed or refractory chronic lymphocytic leukemia ("CLL") or small lymphocytic lymphoma ("SLL") after at least two prior therapies and relapsed or refractory follicular lymphoma ("FL") after at least two prior systemic therapies.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.